Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus

Clinical Rheumatology

Volumn 31, Issue 6, 2012, Pages 951-959

  Zhao, Ling ^a   Jiang, Zhenyu ^a   Jiang, Yanfang ^a   Ma, Ning ^a   Wang, Kai ^a   Zhang, Yandong ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cyclophosphamide; Lymphocyte subsets; Mycophenolate mofetil; Systemic lupus erythematosus

Indexed keywords

C REACTIVE PROTEIN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SM ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; RATING SCALE; SLE DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TURBIDIMETRY; UNSPECIFIED SIDE EFFECT;

ADULT; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MALE; MODELS, STATISTICAL; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 84863724547     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-1958-8     Document Type: Article

References (43)

1. Delves PJ, Roitt IM (2000) The immune system: first of two parts. N Engl J Med 343:37-49
2. Delves PJ, Roitt IM (2000) The immune system: second of two parts. N Engl J Med 343:108-117
3. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340-350
4. Adalid-Peralta L, Mathian A, Tran T et al (2008) Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. Kidney Int 73:172-180
5. Klinman DM, Shirai A, Ishigatsubo Y et al (1991) Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 34(11):1404-1410
6. Portales-Perez D, Gonzalez-Amaro R, Abud-Mendoza C et al (1997) Abnormalities in CD69 expression, cytosolic pH and Ca2 + during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 6:48-56
7. Fernandez-Gutierrez B, de Miguel S, Morado C et al (1998) Defective early T and T-dependent B cell activation in systemic lupus erythematosus. Lupus 7:314-322
8. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189:1639-1648
9. Chan O, Shlomchik MJ (1998) A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 160:51-59
10. Vratsanos G, Kang I, Craft J (2001) Systemic lupus erythematosus. In: Austen KF, Frank MM, Atkinson JP, Cantor H (eds) Samter's immunologic diseases, vol 2. Lippincott Williams & Wilkins, Philadelphia, pp 475-495
11. Herrmann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21:424-426
12. Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G (2009) CXCR3+CD4+T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 60:199-206
13. Robak E, Niewiadomska H, Robak T, Bartkowiak J, Blonski JZ, Wozniacka A, Pomorski L, Sysa-Jedrezejowska A (2001) Lymphocytes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediators Inflamm 10:179-189
14. Park YW, Kee SJ, Cho YN et al (2009) Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60:1753-1763
15. Young-Nan Cho, Seung-Jung Kee, Sung-Ji Lee et al (2011) Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. doi:10.1093/rheumatology/keq457
16. Yabuhara A, Yang FC, Nakazawa T et al (1996) A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 23:171-177
17. Erkeller-Yüsel F, Hulstaart F, Hannet I et al (1993) Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 2:227-231
18. Li W-X, Pan H-F, Jian-Li Hu et al (2010) Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. Clin Rheumatol 29:315-323
19. Sibbitt WL Jr, Mathews PM, Bankhurst AD (1983) Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 71:1230-1239
20. Mercer JC, Ragin MJ, August A (2005) Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37:1337-1343
21. Gapin L, Matsuda JL, Surh CD et al (2001) NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2:971-978
22. van der Vliet HJ, von Blomberg BM, Nishi N et al (2001) Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100:144-148
23. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
24. Blanco P et al (2005) Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52:201-211
25. Viallard JF et al (2001) HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 125:485-491
26. Filaci G, Bacilieri S, Fravega M et al (2001) Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 166(10):6452-6457
27. Spinozzi F, Agea E, Bistoni O et al (1995) T lymphocytes bearing the gamma delta T cell receptor are susceptible to steroid-induced programmed cell death. Scand J Immunol 41:504-508
28. Jiang M, Sun HY, Zu LP (1991) Studies on the T4+2H4+ cell of peripheral blood lymphocyte in systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 30(426-8):57
29. Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93-151
30. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176:3498-3506
31. Mamula MJ, Lin RH, Janeway CA Jr, Hardin JA (1992) Breaking T cell tolerance with foreign and self coimmunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J Immunol 149:789-795
32. Greenfield EA, Nguyen KA, Kuchroo VK (1998) CD28/B7 costimulation: a review. Crit Rev Immunol 18:389-418
33. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 2008, 9:503-510
34. Shj FD,Wang HB, Li H et al (2000) Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1:245-251
35. TakahashiK AT, Endoh M et al (2004) The regulatory role of natural killer cells in multiple sclerosis. Brain 127:1917-1927
36. Ortaldo JR, Mason AT, O'Shea JJ (1995) Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 181:339-344
37. Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A et al (2001) A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 44:884-892
38. Stetson DB, Mohrs M, Reinhardt RL et al (2003) Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 198:1069-1076
39. Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKTcells. J Clin Invest 114:1379-1388
40. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM (2004) Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 43:377-380
41. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219-2228
42. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J (2010) Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 25:3939-3948
43. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103-1112